Streetbeat News

ALPMY

Astellas Pharma Inc.

https://www.astellas.com/jp/

CEO

Kenji Yasukawa

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Takeda, Astellas, and SMBC have partnered to establish Ciconia Bioventures, a venture focused on early-stage drug discovery in Japan. This collaboration aims to drive innovation in the pharmaceutical sector.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 6:24 am

Astellas has announced the FDA listing of DIGITIVA, a non-invasive digital health solution for heart failure management, allowing patients to monitor their condition at home.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 7:21 am

The European Commission has approved Astellas' PADCEV in combination with KEYTRUDA for the first-line treatment of advanced urothelial cancer. This regimen has shown superiority over the traditional platinum-containing chemotherapy, based on positive results from the Phase 3 EV-302 trial.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 6:53 am

Astellas has initiated a Phase 3 trial for fezolinetant, targeting vasomotor symptoms in women with hormone receptor-positive breast cancer undergoing adjuvant endocrine therapy. The study, named HIGHLIGHT 1™, aims to address moderate to severe symptoms in patients with stage 0-3 cancer.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:15 am

Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:27 pm

Astellas Pharma has received a positive opinion from the CHMP for its drug zolbetuximab, which targets CLDN18.2, for the treatment of advanced gastric and gastroesophageal junction cancer. If approved by the European Commission, it would be the first CLDN18.2-targeted therapy in the EU, with a decision expected by October 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 3:48 pm

Astellas Pharma has received a positive opinion from the CHMP for the approval of PADCEV in combination with KEYTRUDA for the first-line treatment of advanced bladder cancer. This combination could become the first alternative to platinum-containing chemotherapy, showing nearly double the median overall survival in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 3:47 pm

Astellas has announced a collaboration with YASKAWA to develop an innovative cell therapy ecosystem by integrating pharmaceutical and robotics technologies.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 4:59 am

Astellas and Poseida Therapeutics have entered into a research collaboration and license agreement to develop novel allogeneic cell therapies for oncology, focusing on solid tumors using Poseida's proprietary allogeneic CAR-T platform.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 7:29 am

Astellas' XTANDI (Enzalutamide) has received approval from the European Commission for use in a new treatment setting for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the EU. This makes XTANDI the first novel hormone therapy available for this condition in the EU. The approval is based on the positive results from the Phase 3 EMBARK study, which demonstrated that XTANDI, alone or in combination with leuprolide, significantly reduced the risk of metastasis or death.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 6:23 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.